280,335 Shares in Mirion Technologies, Inc. (NYSE:MIR) Purchased by Paradoxiom Capital L.P.

Paradoxiom Capital L.P. acquired a new position in Mirion Technologies, Inc. (NYSE:MIR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 280,335 shares of the company's stock, valued at approximately $4,892,000. Paradoxiom Capital L.P. owned 0.12% of Mirion Technologies as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in MIR. US Bancorp DE boosted its stake in shares of Mirion Technologies by 3,248.7% in the fourth quarter. US Bancorp DE now owns 6,262 shares of the company's stock worth $109,000 after acquiring an additional 6,075 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Mirion Technologies by 162.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,649 shares of the company's stock worth $116,000 after buying an additional 4,120 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Mirion Technologies in the fourth quarter worth about $120,000. KBC Group NV lifted its position in shares of Mirion Technologies by 39.2% in the fourth quarter. KBC Group NV now owns 8,002 shares of the company's stock worth $140,000 after buying an additional 2,254 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in shares of Mirion Technologies in the fourth quarter worth about $187,000. Institutional investors own 78.51% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MIR shares. Robert W. Baird decreased their price objective on Mirion Technologies from $22.00 to $20.00 and set an "outperform" rating on the stock in a research report on Friday, April 4th. B. Riley dropped their price objective on Mirion Technologies from $19.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, April 16th. Finally, Citigroup dropped their target price on Mirion Technologies from $20.00 to $17.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Mirion Technologies has a consensus rating of "Buy" and a consensus price target of $18.75.

Mirion Technologies Stock Down 0.1%

Shares of MIR traded down $0.01 during midday trading on Monday, hitting $17.22. 442,535 shares of the company's stock traded hands, compared to its average volume of 1,701,877. The stock has a market capitalization of $3.99 billion, a price-to-earnings ratio of -90.58 and a beta of 0.74. The company has a current ratio of 2.16, a quick ratio of 1.55 and a debt-to-equity ratio of 0.43. The firm's fifty day moving average is $14.91 and its 200-day moving average is $15.85. Mirion Technologies, Inc. has a 1 year low of $9.11 and a 1 year high of $18.81.

Mirion Technologies (NYSE:MIR - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.02. The business had revenue of $202.00 million during the quarter, compared to analyst estimates of $199.34 million. Mirion Technologies had a positive return on equity of 4.78% and a negative net margin of 4.21%. The company's revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business posted $0.06 EPS. As a group, sell-side analysts anticipate that Mirion Technologies, Inc. will post 0.39 earnings per share for the current year.

About Mirion Technologies

Mirion Technologies, Inc provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, South Korea, and Japan. It operates through two segments, Medical and Technologies.